BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38523596)

  • 1. Indirect comparisons of relative efficacy estimates of zuranolone and selective serotonin reuptake inhibitors for postpartum depression.
    Meltzer-Brody S; Gerbasi ME; Mak C; Toubouti Y; Smith S; Roskell N; Tan R; Chen SS; Deligiannidis KM
    J Med Econ; 2024; 27(1):582-595. PubMed ID: 38523596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using Matching-Adjusted Indirect Comparisons and Network Meta-analyses to Compare Efficacy of Brexanolone Injection with Selective Serotonin Reuptake Inhibitors for Treating Postpartum Depression.
    Cooper MC; Kilvert HS; Hodgkins P; Roskell NS; Eldar-Lissai A
    CNS Drugs; 2019 Oct; 33(10):1039-1052. PubMed ID: 31642037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of zuranolone versus selective serotonin reuptake inhibitors for the treatment of postpartum depression in the United States.
    O'Callaghan L; Chertavian E; Johnson SJ; Ferries E; Deligiannidis KM
    J Med Econ; 2024; 27(1):492-505. PubMed ID: 38465615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial.
    Deligiannidis KM; Meltzer-Brody S; Gunduz-Bruce H; Doherty J; Jonas J; Li S; Sankoh AJ; Silber C; Campbell AD; Werneburg B; Kanes SJ; Lasser R
    JAMA Psychiatry; 2021 Sep; 78(9):951-959. PubMed ID: 34190962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Brexanolone Versus Selective Serotonin Reuptake Inhibitors for the Treatment of Postpartum Depression in the United States.
    Eldar-Lissai A; Cohen JT; Meltzer-Brody S; Gerbasi ME; Chertavian E; Hodgkins P; Bond JC; Johnson SJ
    J Manag Care Spec Pharm; 2020 May; 26(5):627-638. PubMed ID: 32191592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials.
    Clayton AH; Suthoff E; Jain R; Kosinski M; Fridman M; Deligiannidis KM; Meltzer-Brody S; Chen SY; Gervitz L; Huang MY; Trivedi M; Bonthapally V
    J Affect Disord; 2024 Apr; 351():904-914. PubMed ID: 38325605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders.
    Walkery A; Leader LD; Cooke E; VandenBerg A
    Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zuranolone: The First FDA-Approved Oral Treatment Option for Postpartum Depression.
    Barnes KN; Vogl CM; Nelson LA
    Ann Pharmacother; 2024 Jul; 58(7):728-734. PubMed ID: 37876133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zuranolone for the Treatment of Postpartum Depression.
    Deligiannidis KM; Meltzer-Brody S; Maximos B; Peeper EQ; Freeman M; Lasser R; Bullock A; Kotecha M; Li S; Forrestal F; Rana N; Garcia M; Leclair B; Doherty J
    Am J Psychiatry; 2023 Sep; 180(9):668-675. PubMed ID: 37491938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression.
    Deligiannidis KM; Citrome L; Huang MY; Acaster S; Fridman M; Bonthapally V; Lasser R; Kanes SJ
    J Clin Psychiatry; 2023 Jan; 84(1):. PubMed ID: 36724109
    [No Abstract]   [Full Text] [Related]  

  • 11. The efficacy of zuranolone versus placebo in postpartum depression and major depressive disorder: a systematic review and meta-analysis.
    Winslow M; White E; Rose SJ; Salzer E; Nemec EC
    Int J Clin Pharm; 2024 Jun; 46(3):590-601. PubMed ID: 38489051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zuranolone: A Narrative Review of a New Oral Treatment for Postpartum Depression.
    Hitt EM
    Clin Ther; 2024 May; 46(5):433-438. PubMed ID: 38697873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zuranolone, a neuroactive drug, used in the treatment of postpartum depression by modulation of GABA
    Sharma R; Bansal P; Saini L; Sharma N; Dhingra R
    Pharmacol Biochem Behav; 2024 May; 238():173734. PubMed ID: 38387651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of zuranolone for the treatment of depression: A systematic review and meta-analysis.
    Li Z; Wu Q; Peng P; Wu M; Liu S; Liu T
    Psychiatry Res; 2024 Jan; 331():115640. PubMed ID: 38029628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidepressant treatment for postnatal depression.
    Brown JVE; Wilson CA; Ayre K; Robertson L; South E; Molyneaux E; Trevillion K; Howard LM; Khalifeh H
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013560. PubMed ID: 33580709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective serotonin reuptake inhibitors (SSRIs) for post-partum depression (PPD): a systematic review of randomized clinical trials.
    De Crescenzo F; Perelli F; Armando M; Vicari S
    J Affect Disord; 2014 Jan; 152-154():39-44. PubMed ID: 24139299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of some new GABAkines for treatment of depression: A systematic review and meta-analysis from randomized controlled trials.
    Zou J; Yang L; Yang G; Gao J
    Psychiatry Res; 2023 Oct; 328():115450. PubMed ID: 37683318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidepressant treatment for postnatal depression.
    Molyneaux E; Howard LM; McGeown HR; Karia AM; Trevillion K
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD002018. PubMed ID: 25211400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between commonly used patient-reported outcome tools in postpartum depression clinical practice and the Hamilton Rating Scale for Depression.
    Gerbasi ME; Eldar-Lissai A; Acaster S; Fridman M; Bonthapally V; Hodgkins P; Kanes SJ; Meltzer-Brody S
    Arch Womens Ment Health; 2020 Oct; 23(5):727-735. PubMed ID: 32666402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis.
    Cha DS; Kleine N; Teopiz KM; Di Vincenzo JD; Ho R; Galibert SL; Samra A; Zilm SPM; Cha RH; d'Andrea G; Gill H; Ceban F; Meshkat S; Wong S; Le GH; Kwan ATH; Rosenblat JD; Rhee TG; Mansur RB; McIntyre RS
    Expert Opin Pharmacother; 2024; 25(1):5-14. PubMed ID: 38164653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.